Authored by James Sheppard
Global pharmaceutical giant Pfizer has signed a deal with tiny US biotech Gliknik for the experimental drug GL-2045. GL-2045 is being developed for the treatment of autoimmune diseases and cancer. As part of the deal, Gliknik will receive $25m in upfront payment and is eligible to receive developmental milestone payments as well as double digit royalties.
GL-2045 is a recombinant stradomer, designed to replace and improve on pooled human intravenous immunoglobulin (IVIG), which is used to boost the immune system. GL-2045 has shown promising results in pre-clinical tests, and is being developed for a wide variety of autoimmune diseases, including those where IVIG is clinically used. GL-2045 is now in IND-enabling manufacturing.
David Block, CEO of Gliknik said ‘GL-2045 is the first of several innovative drug candidates Gliknik is advancing for people with autoimmune diseases and cancer. We selected Pfizer as our partner to progress GL-2045 from among several interested and capable parties because of its exceptional development, manufacturing and commercial capabilities.’
Gliknik, founded in 2007, is currently developing 4 products including GL-2045. The remaining 3 products are immunomodulators which are being tested in cancer and are currently in multi-dose clinical studies. Gliknik recently raised $4.9m in series B financing which was led by the venture capital arm of global pharma giant Baxter.